GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (NAS:ANIK) » Definitions » Book Value per Share

Anika Therapeutics (Anika Therapeutics) Book Value per Share : $14.48 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics Book Value per Share?

Anika Therapeutics's book value per share for the quarter that ended in Dec. 2023 was $14.48.

During the past 12 months, Anika Therapeutics's average Book Value Per Share Growth Rate was -25.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -8.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -3.60% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Anika Therapeutics was 42.80% per year. The lowest was -24.60% per year. And the median was 11.50% per year.

Anika Therapeutics's current price is $25.98. Its book value per share for the quarter that ended in Dec. 2023 was $14.48. Hence, today's PB Ratio of Anika Therapeutics is 1.79.

During the past 13 years, the highest P/B Ratio of Anika Therapeutics was 4.56. The lowest was 0.93. And the median was 2.38.


Anika Therapeutics Book Value per Share Historical Data

The historical data trend for Anika Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics Book Value per Share Chart

Anika Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.16 19.01 19.88 19.53 14.48

Anika Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.53 18.83 18.70 18.48 14.48

Competitive Comparison of Anika Therapeutics's Book Value per Share

For the Medical Instruments & Supplies subindustry, Anika Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anika Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's PB Ratio falls into.



Anika Therapeutics Book Value per Share Calculation

Anika Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(212.3-0.0)/14.7
=14.48

Anika Therapeutics's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(212.3-0.0)/14.7
=14.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Anika Therapeutics  (NAS:ANIK) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Anika Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Anika Therapeutics (Anika Therapeutics) Business Description

Traded in Other Exchanges
Address
32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
Executives
Anne Nunes officer: SVP, Chief Operations Officer 32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti director 600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran officer: EVP, General Counsel, Corp Sec 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard director C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz officer: EVP, CFO, Treasurer C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land director
Stephen Richard director C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop officer: EVP Business Development C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung officer: CFO ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen director 32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower director 32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson director 1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling officer: President 501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767